-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 7, Genting Sunyao announced that the Singapore Health Sciences Authority (HSA) has approved Trodelvy® (gosatuzumab) for the treatment of patients who have received at least two prior systemic therapies (at least one of which is for metastatic disease).
In addition to Singapore, the relevant regulatory agencies in Greater China and South Korea have accepted relevant review applications for Trodelvy for the treatment of unresectable patients who have received at least two prior systemic therapies, at least one of which is for metastatic disease.
In May 2021, China's National Medical Products Administration accepted Trodelvy's biological product marketing authorization application and granted priority review
In December 2021, the Korean Ministry of Food and Drug Safety (MFDS) accepted the new drug application for Trodelvy
In December 2021, the Taiwan Food and Drug Administration accepted the new drug marketing application for Trodelvy